From The Stage
← Back to From The Stage
Dr. Afshin Safavi
Posted by Dr. Afshin Safavi BioAgilytix Insight, Biomarkers, Uncategorized

New Paths for Biomarker Development: Clearing the Way for Faster Innovation

New Paths for Biomarker Development: Clearing the Way for Faster Innovation

This spring, I attended The Biomarker Conference in San Diego along with other biomarker experts to discuss best practices for an industry that is still maturing in areas such as discovery, development, clinical application, and regulatory approval. A range of topics were covered, from identifying accurate biomarkers to developing standard protocols. At the end of the event, I was left with an exciting takeaway: that while there are still many complexities involved in bringing new biomarkers to the clinic, much progress is already being made to create clearer paths for overcoming biomarker development challenges.

Presenters at the conference reported progress in several key areas, from the integration of next-generation sequencing (NGS) to advance clinical cancer genomics to leveraging biomarkers to tune immunosuppression and prevent chronic rejection of transplants. I was able to give a presentation as well, which focused on a process innovation that we’ve created here at BioAgilytix, which we call MultiMuscle Analysis™. We developed this technique in response to the trend we’ve been seeing the biomarker field, where large pharma is moving away from a gunshot approach and instead focusing analyses on a few key biomarkers. Additionally, limited samples may drive the desire to multiplex as many biomarkers as possible, but a multiplex approach may often result in low quality data due to reagent cross-reactivity.

Our MultiMuscle Analysis overcomes the traditional weaknesses of multiplex assays as a customized parallel process that splits sample analysis into multiple parallel tracks, each performed on specialized equipment by scientists experienced on that particular platform. Not only does this process minimize antibody cross-reactivity, it also allows us to use the best-fit platform or kit for each biomarker analysis.


If for example a customer requests measurement of 10 biomarkers, and we know some of the antibodies may cross-react, then we may end up running one heptaplex and three uniplexes all in parallel. Using this approach, we are able to perform large biomarker analyses on a very large number of samples in near real-time.

BioAgilytix has become a world leader in considering and mitigating the variable factors that innately go along with large molecule bioanalysis. Designing effective analytical processes requires deep scientific expertise, and we are proud to be on the leading edge of such development in the biomarker field, along with the other experts who presented at The Biomarker Conference. For a more detailed recap of the topics discussed at this year’s show, check out the article “Paving the Road for Clinical Biomarkers” at Genetic Engineering & Biotechnology News. Also feel free to email me directly with any questions you may have regarding large molecule bioanalysis for your biomarker studies.

Share This